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Since its introduction in the late 1950s, isolated limb perfusion (ILP) has been the preferred treatment option for locally advanced
melanoma and sarcoma conﬁned to a limb. This treatment results in high response rates with a satisfying duration of response
in both tumor types. A drawback of ILP, however, is the invasive and complex character of the procedure. Isolated limb infusion
(ILI) has been designed in the early 1990s as a minimally invasive alternative to ILP. Results of this simple procedure, reported by
various centers around the world, show comparable response rates for melanoma and sarcoma when compared to ILP. Due to its
minimally invasive character, ILI may replace ILP in the future as the preferred treatment for these locally advanced limb tumors.
1.Introduction
Patients who suﬀer from advanced melanoma or sarcoma
conﬁned to a limb are often challenging to treat due to the
size and number of the satellite and/or in-transit metastasis
in melanoma or the invasion of the tumor in sarcoma. In
the past, results of systemic therapies in these tumours have
often been disappointing. Although promising results have
beenpublishedusingipilimumabandRG7204formetastatic
melanoma, little is known about the eﬀect of these agents
when metastases are limited to a limb [1–4]. In the past
an amputation was often inevitable but since the late 1950s
this mutilating procedure can be avoided in the majority of
patients by performing an isolated limb perfusion (ILP).
During ILP the blood circulation of the limb is tem-
porarily discontinued from the systemic circulation. With
a surgical procedure the femoral artery and vein (when
treating a leg) or the axillary artery and vein (when treating
an arm) are clamped and connected to an extracorporeal
circuit containing a heart-lung machine in order to preserve
physiological circumstances in the isolated limb. To achieve
optimal isolation, minor vessels of subcutaneous tissues and
muscles are compressed by a tourniquet. In this isolated
circuit the dose of the cytotoxic drug, normally melphalan,
can be safely applied up to a tenfold higher than systemically
tolerated without compromising locally irreversible adverse
eﬀects [4–6]. Since ﬂow of the cytotoxic drug to the systemic
circulation could result in a life-threatening situation, poten-
tial leakage is continuously monitored during the procedure
[7]. The cytotoxic drug circulates typically 60 to 90 minutes
after which the limb is ﬂushed to discard the remaining
drugs in the isolated limb. The procedure is ﬁnalized by
surgicallydisconnectingthetubesoftheheart-lungmachine,
closing the vessels with sutures or a patch and deﬂating the
tourniquet to restore the normal circulation in the limb.
Following ILP for melanoma complete response (CR)
percentages of 7–91 (median 46) and partial response (PR)
percentages of 0–44 (median 34) are reported. The median
recurrence-free survival is 14 months, which is 23 months
(range 8– > 72) following a CR. Overall survival following
ILP is 24 months and 44 months (IQR 22– > 120) after a CR
[4, 8, 9]. In patients with locally advanced sarcoma response
percentages of 63–91 are reported [5, 10]. In both patient
groups ILP can prevent amputation of the aﬀected limb in
90% of the cases.
Despite these excellent results, ILP has some major
disadvantages. It is an invasive and technically complex2 Journal of Skin Cancer
Table 1:Meanbloodgasvaluesoftheisolatedlimbafter30minutes
in 185 patients [17].
pO2 8.4mmHg
pCO2 54.3mmHg
pH 7.11
BE −10.8mmol/L
SO2 6.9%
procedure in which not only a surgeon is involved but also
a perfusionist and a large number of supporting staﬀ are
needed [11]. Although some have reported that ILP can
be performed safely in elderly and frail patients, it is only
performed in carefully selected patients [12–14]. Finally, a
repeat ILP, after disease recurrence, is complex and can result
in major complications due to scar tissue from the previous
surgical approach of the vessels.
2. IsolatedLimb Infusion
In the early 1990s the isolated limb infusion (ILI) technique
was developed by Thompson and colleagues at the Sydney
Melanoma Unit (currently Melanoma Institute Australia;
MIA) as a simpliﬁed and minimally invasive alternative to
ILP [25]. In contrast to ILP, during ILI no invasive surgical
approach is needed. Radiological catheters with additional
side holes near their tips are inserted percutaneously into
the axial artery (6 French) and vein (8 French) of the
disease-bearing limb via the contralateral groin using the
Seldinger technique. Their tips are positioned in such a
way that they are at the level of the knee or elbow joint.
Tissues more proximally located in the limb but distal to
the level of the tourniquet were perfused in a retrograde
fashion via collateral vascular channels. The patient is then
given a general anesthetic, and heparin (3mg/kg) is infused
to achieve full systemic heparinization. The catheters are
connected to an extracorporeal circuit ﬁlled with saline
solution incorporating a blood-warming coil but without
a heart-lung machine. A pneumatic tourniquet is inﬂated
around the root of the to be treated limb, and the cytotoxic
agents are infused into the isolated circuit via the arterial
catheter. In this isolated circuit a low-ﬂow circulation can be
realized without oxygenating the circulated blood resulting
in a hypoxic and acidotic environment (Table 1)[ 17]. The
cytotoxic drugs that are used are melphalan 5–10mg/L of
tissue (mostly 7.5mg/L) and actinomycin-D 50–100μg/L
of tissue (mostly 75μg/L) in 400mL warmed, heparinized
normal saline. Actinomycin-D is used because of the good
response rates (CR 73%) of the melphalan/actinomycin-
D combination when administered by conventional ILP,
without excessive limb toxicity [26].
After infusion of the drugs in the isolated circuit the
infusate is continually circulated for 30 minutes by repeated
aspiration from the venous catheter and reinjection into the
arterial catheter using a syringe attached to a three-way tap
in the external circuit.
Since the half time of melphalan is 15 to 20 minutes and
both melphalan and actinomycin-D are quickly absorbed by
the tissues of the isolated limb, a relative short circulation
time of 30 minutes is suﬃcient [27, 28].
Great care is given to the limb temperature since cooling
of the extremity has a negative eﬀect on the eﬃcacy of
the cytotoxic drugs. Heating of the limb is achieved by the
aforementioned blood-warming coil in the extracorporeal
circuit and by encasing the limb in a hot-air blanket, with
a radiant heater placed over it [6]. Subcutaneous and intra-
muscular limb temperatures are monitored continuously
during the ILI procedure. If these precautions are taken
into account it is possible to achieve limb temperatures just
above 40◦C. Blood samples are taken at regular intervals
to measure the melphalan concentrations and blood gases
(Table 1). The drug leakage rate from the isolated limb is
assessed retrospectively on the basis of systemic melphalan
concentrations that are measured routinely during each
procedure. Intraoperative systemic leakage monitoring is not
performed because systemic leakage is negligibly low due to
thelow-ﬂowandlow-pressurecircuitoftheisolatedlimband
the eﬀective isolation using the tourniquet.
After 30 minutes, the limb is ﬂushed with one liter of
Hartmann’s solution via the arterial catheter, and the venous
eﬄuent was discarded. The tourniquet is then deﬂated to
restore normal limb circulation, the heparin is reversed with
protamine, and the cathetersare removed [29]. Figures 1 and
2 provide an overview of the procedure [15, 16].
Postoperatively the serum creatine phosphokinase (CK)
level is measured daily as an indicator for muscle and tissue
breakdown, and limb toxicity, systemic toxicity, and tumor
response are assessed regularly.
3. Results of IsolatedLimb Infusion
Since 1992 over 400 ILIs have been performed in the MIA,
mostly for melanoma but also for patients with locally
advanced sarcoma. Following ILI a CR rate of 38% and a
PR of 46% are seen in patients suﬀering from melanoma
(Figure 3)[ 17]. The median LRFI in these patients was 13
months and 22 months (range 5 to >72: P = .012) for those
experiencing a CR. The median survival following a CR was
53 months (range 28 to >120), 26 months (range 14 to >120)
following a PR, and only 6 months for the small group of
patients who had stable or progressive disease following the
procedure (P = .004). These results are comparable to those
reported after ILP [30, 31]. To date only one multicenter
r e t r o s p e c t i v ea n a l y s i sf o rI L Ih a sb e e np u b l i s h e d[ 18]. In this
analysis 31% of the patients experienced a CR, 33% a PR,
and36%showednoresponsetothetreatment.Inadditionto
these institutions a number of institutions around the world
have reported their experiences. These are listed in Table 2
[18–22]. The wide range of the results in these studies is
possibly caused by the low number of patients in some of the
studies and possibly by the lack of experience with this new
technique. Furthermore, all institutes have used a protocol
that is diﬀerent in very small, but potentially essential, ways.
The impact of these diﬀerences in protocol and the eﬀect
of increased experience have recently been investigated by
Huismans et al. [32]. They showed that increased experienceJournal of Skin Cancer 3
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Figure 1: Schematic illustration of the circuit used for isolated infusion of a lower limb [15].
Figure 2: Photograph of an isolated limb infusion procedure in progress in the operating theatre [16].
and small modiﬁcations that were made to the ILI protocol
at the MIA over the years resulted in a positive eﬀect on
the outcome. Another explanation for the reported range in
results could be the point in time when the response of the
procedure was investigated. Beasley et al., for instance, took
theresponseafterexactly3monthswhileotherstookthebest
response at any time after ILI [20]. Despite the diﬀerences in
experience, protocol, and outcome, most investigators have
reported that patients who obtain a CR have signiﬁcantly
improved survival compared with nonresponders [20, 22].
The experience in using ILI for inoperable sarcoma is
still limited, to two studies. However, the results reported4 Journal of Skin Cancer
(a) (b)
(c)
Figure3:(a)Extensivein-transitmelanomametastasesoftheleftlowerlegbeforeILI.(b)Remission4weekspost-ILI.(c)Completeresponse
4 months post-ILI.
Table 2: Isolated limb infusion studies using melphalan and actinomyocin-D [17–23].
Author, year No. of patients Response criteria CR PR SD PD
Mian et al., 2001 [19]9 ∗ Best response 44% 56% 0% 0%
Lindn´ er et al., 2002 [21] 128 Best response 41% 43% 12% 4%
Brady et al., 2006 [23]2 2 ∗∗ 3 months 23% 27% 0% 50%
Kroon et al., 2008 [17] 185 Best response 38% 46% 10% 6%
Beasley et al., 2008 [20] 50 3 months 30% 14% 10% 46%
Marsden, 2008 [24]1 6 ∗∗∗ Unknown 26% 58% — 16%
Barbour et al., 2009 [22] 74 Best response 24% 30% 37% 7%
Beasley et al., 2009 [18] 128 3 months 31% 33% 7% 29%
CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.
∗3 patients had >1I L I s .
∗∗1 patient had advanced sarcoma.
∗∗∗3 patients had >1 ILIs, 4 patients had squamous cell carcinoma, and 2 patients had Merkel cell carcinoma.
are comparable to those seen after ILP [16, 23]. In these
two separate studies CR rates of 23 and 57% and PR rates
of 27 and 33% were reported with a median LRFI of 15
months. Following ILI amputation of the aﬀected limb could
be avoided in 76–94% of the sarcoma patients.
Following ILI the regional toxicity due to the cytotoxic
drug is low [20, 25, 33]. Slight erythema and oedema are
seen in 41–57% of the patients, and in 39–53% this is
accompanied with the forming of blisters. In most cases
a conservative treatment involving bed rest, elevation, and
sometimes administering steroids is suﬃcient. In 3% of the
patients the deeper tissues are involved, and in order to
prevent a compartment syndrome a fasciotomy is sometimes
carried out. To date at the MIA, it has not been necessary
to amputate a limb due to severe tissue damage following
ILI with melphalan and actinomycin-D. A study focusingJournal of Skin Cancer 5
Table 3: Diﬀerences between isolated limb perfusion and isolated limb infusion.
Isolated limb perfusion Isolated limb infusion
Technically complex Technically simple
Open surgical exposure of vessels for catheter insertion Percutaneous vascular catheter insertion in radiology department
4 to 6 hours duration Approximately 1 hour
Perfusionist and large number of staﬀ required No perfusionist required and fewer total staﬀ
Complex and expensive equipment needed Equipment requirements modest
Magnitude of procedure excludes patients Well tolerated by medically compromised, frail, and elderly patients
Not possible in occlusive vascular disease Can be performed in occlusive vascular disease
Technically challenging to perform a repeat procedure Not diﬃcult to perform a repeat procedure
Systemic metastases normally a contraindication Systemic metastases not a contraindication
Higher perfusion pressures predispose to systemic leakage Low pressure system, eﬀective vascular isolation with tourniquet
Limb tissues oxygenated, with normal blood gases maintained Progressive hypoxia and acidosis
Hyperthermia (>41◦C can be achieved) Usually not possible to raise limb temperature above 40◦C
General anesthesia required Possible with regional anesthesia
on toxicity showed that patients with larger limb volumes
experience increasedtoxicity grades withoutreceiving higher
cytotoxic drug doses [34] .I no r d e rt od e c r e a s et h et o x i c i t y
rates in these patients Beasley et al. corrected the melphalan
dose for ideal body weight (IBW) [35]. In their hands this
decreased toxicity signiﬁcantly (P = .001) with only a small
insigniﬁcant decrease in response (P = .345). However, these
results could not be reproduced in a study initiated by the
MIA in which the ratio of IBW and actual body weight did
not predict toxicity or outcome (unpublished data) [36].
4. Discussion
One of the main advantages of ILI is the minimally invasive
character of the procedure.
Morbidity as a result of the surgical approach of the
blood vessels as seen in ILP is not experienced, and normally
patients can be discharged from the hospital 7 days after
the procedure [32, 34]. ILI can also safely be performed
in elderly and frail patients without risking severe adverse
eﬀects. No increase in toxicity or morbidity was seen in the
MIA patients, despite the fact that their average age was
considerably higher than those seen in most ILP studies
[17, 37]. Even in patients who suﬀer from distant metastatic
disease and concurrent symptomatic limb disease ILI can
eﬀectively be used as a palliative treatment to provide local
tumorcontrolandlimbsalvage[38].Also,becausescartissue
is hardly formed following ILI, the procedure can easily be
repeated in case of recurrent disease. The response rates of
these repeat procedures are comparable to those seen after a
ﬁrst ILI [39].
Another advantage of ILI is the hypoxemia and acidosis
in the isolated limb. Animal studies have shown that a
hypoxic and acidotic environment enhances the eﬀect of
melphalan by a factor 3 [40]. Clinically enhanced responses
were observed when isolation of the limb lasted longer than
40 minutes [21].
Furthermore, ILI has a number of practical advantages
over ILP. The time in the operating theatre is considerably
shorter (on average one hour compared to 3–5 hours for
ILP), no complex and expensive equipment is used, and
less personnel is needed [29]. Because of this, ILI is a
much cheaper procedure. Finally, ILI is often used in trial
settings to provide insight for developing novel treatment
strategies [41]. One of these studies used systemic ADH-1
in combination with melphalan. It was well tolerated and
p r o v i d e daC Ro f5 0 %[ 42]. In Table 3 diﬀerences between
ILI and ILP are listed.
5. Conclusion
OverthelasttwodecadesILIhasbecomeaseriousalternative
to the traditionally used ILP technique. Studies, most pub-
lished in the recent years, have shown that, when performed
correctly, response rates following ILI are comparable to
those seen after ILP. ILI, however, results in less toxicity and
morbidity. In the future more research and in particular a
randomized controlled trial is needed to prove the eﬀect
of ILI, and it is not unthinkable that ILI will become the
preferred treatment for patients who suﬀer from advanced
melanoma or sarcoma conﬁned to a limb.
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